Can-Fite BioPharma Ltd.

Regulatory Filings • Feb 23, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934

For the Month of February 2023

001-36203 (Commission File Number)

CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter)

10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On February 22, 2023, a Special General Meeting of Shareholders of Can-Fite BioPharma Ltd. (the "Company") approved each of the two proposals brought before the Company's shareholders at the meeting, in accordance with the majority required for each proposal. Each of those proposals was described in the Company's Notice and Proxy Statement with respect to the Company's Special General Meeting of Shareholders, dated January 13, 2023, attached as Exhibit 99.1 to the Company's Form 6-K that was furnished to the U.S. Securities and Exchange Commission on January 13, 2023.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: February 22, 2023 By: /s/ Pnina Fishman

Pnina Fishman Chief Executive Officer